Conference Track

Advances in HBV Treatment With Approved Agents

Source: CCO Official Conference Coverage of the 2008 AASLD Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Treatment With Tenofovir for 96 Weeks Results in High Rate of HBV DNA Suppression in Patients With HBeAg-Negative Chronic HBV Infection
Tenofovir Provides Effective and Sustained Virologic Suppression in HBeAg-Positive HBV-Infected Patients Through 96 Weeks
Low Rate of HBV Recurrence When Antiviral Therapy and HBIG Given Together as Prophylaxis After Liver Transplantation
Rituximab Administration Associated With Reactivation of Hepatitis B
Predictors of HBsAg Loss in HBeAg-Negative Patients Following Long-term Adefovir Treatment Identified
Higher Rates of Virologic Suppression With 6 Months of Entecavir vs Adefovir or Adefovir Plus Lamivudine Treatment in Lamivudine-Resistant Patients Awaiting OLT
Long-term Entecavir Treatment Results in Durable HBV Suppression in Treatment-Naive, HBeAg-Positive Patients
Clinical Experience in Italy Confirms Efficacy and Low Resistance Rates With Entecavir in Nucleos(t)ide-Naive Patients With Chronic Hepatitis B
Week 12 On-Treatment HBsAg Level Predicts Long-term Posttreatment Virologic Response in Patients With HBeAg-Negative Chronic Hepatitis B Infection Treated With Peginterferon alfa-2a ± Lamivudine
Small Retrospective Study Finds Switching to Tenofovir Possibly a Viable Option for HBV-Infected Patients With Suboptimal Response to Entecavir
Liver Fibrosis and Cirrhosis Present in Many Non-Asian Patients With Chronic HBV Infection and Normal or Moderately Elevated ALT Levels
Peginterferon alfa-2a Response Rates in HBeAg-Positive Korean Patients With Lamivudine Resistance Similar to Lamivudine-Naive Patients
Entecavir Combined With Tenofovir Effective and Well Tolerated in Cirrhotic HBV-Infected Patients With Multidrug-Resistant HBV

Expert Analysis

Advances in HBV Treatment With Approved Agents

Faculty:

Jules L. Dienstag, MD
Robert G. Gish, MD
Ira M. Jacobson, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new data on the efficacy and safety of approved antiviral agents for the frontline treatment of chronic HBV infection
Discuss the efficacy of frontline treatments for HBV infection in preventing or managing HBV resistance
Describe factors associated with long-term response to antiviral therapy in patients with chronic hepatitis B
Compare potential switch strategies for patients failing first-line antiviral treatment for chronic HBV infection
Recount data on HBV reactivation in carriers treated with immunomodulatory therapy

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: December 24, 2008

Expiration Date: December 23, 2009

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.